AstraZeneca teams up with Deep Matter for AI drug development; Cancer biotech ImmunOs raises $15M
→ AstraZeneca is aligning itself with the big data company DeepMatter, which is focused on attaining reproducibility in chemistry. The latter is set to help the British drugmaker improve its compound synthesis productivity by using an AI-powered platform to capture real-time data to track factors such as temperature, pressure, ultraviolet light levels and other factors in combination with data on solvents, catalysts, and reagents. “By capturing in-situ chemical data alongside the experimental intent, observations and outcomes, it is expected that machine learning and AI algorithms could yield cost and time savings whilst also providing novel insights into chemistry,” the companies said on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.